The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC).
R. Borson
No relevant relationships to disclose
W. G. Harker
No relevant relationships to disclose
J. E. Reeves
No relevant relationships to disclose
D. Drosick
No relevant relationships to disclose
J. T. Beck
Research Funding - Bristol-Myers Squibb; Genentech; Lilly
S. J. Hager
No relevant relationships to disclose
W. L. Horvath
No relevant relationships to disclose
J. Bromund
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
H. Zeigler
No relevant relationships to disclose
D. Tai
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
D. A. Yardley
No relevant relationships to disclose